RenovoRx Inc (RNXT NASDAQ) stock market data APIs
$0.9724
0.01(1%)
as of February 9, 2026
Try our APIs with
free plan!
RenovoRx Inc Financial Data Overview
Price chart is built with
Anychart
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Prev. Close
0.9724
Open
0.9787
High
1.0276
Low
0.9568
52 wk Range
0.701-1.45
Market Cap
36 283 K
Shares Outstanding
36 650 K
Revenue
928 K
EPS
-0.08
Beta
1.312
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with RenovoRx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RenovoRx Inc data using free add-ons & libraries
Get RenovoRx Inc Fundamental Data
RenovoRx Inc Fundamental data includes:
- Net Revenue: 928 K
- EBITDA: -11 390 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RenovoRx Inc News
New
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – Biopharma M&A is entering a fever pitch, with precis...
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates
(RTTNews) - Several biotechnology and healthcare companies posted notable gains in after-hours trading on Wednesday, driven by clinical updates, financial results, and upcoming industry presentations....
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers
(RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. Novo Nordisk A/S (NVO) surge...
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength
(RTTNews) - Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments. Kura O...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
